Voya Asia Pacific High Dividend Equity Income Fund T.IAE

Primary Symbol: IAE

Voya Asia Pacific High Dividend Equity Income Fund (the Fund) is a diversified, closed-end management investment company. The Fund’s investment objective is total return through a combination of current income, capital gains and capital appreciation. The Fund seeks to achieve its investment objective by investing primarily in a portfolio of dividend yielding equity securities of Asia Pacific companies. The Fund will seek to achieve its investment objective by investing at least 80% of its managed assets in dividend producing equity securities of, or derivatives having economic characteristics similar to the equity securities of Asia Pacific Companies that are listed and traded principally on Asia Pacific exchanges. The Fund will invest in approximately 60-120 equity securities and will select securities through a bottom-up process that is based upon quantitative screening and fundamental analysis. Voya Investments, LLC is an investment adviser of the Fund.

NYSE:IAE - Post by User

Voya Asia Pacific High Dividend Equity Income Fund > FPF-1 value

<< Previous

Bullboard Posts

Next >>

Comment by Doug2Bon Aug 12, 2016 11:08am

88 Views

Post# 25135613

RE:RE:RE:RE:RE:RE:RE:FPF-1 value

Keith

Worth digging into this further I think. I did not fully understand the position and I am not quite sure I fully do now although your post has shed a lot more light on this.

Why would petrofac have agreed to do the additional work that it is often assumed they agreed to, perhaps after the initial flow tests they realised that there was enough throughput from Stella/Harrier to fill their boots. But is does surprise me that Petrofac don't seem to be tied into FPF-1 throughput from additional fields as well.

Your suggestion that analysts don't fully realise the apparent strength of the Ithaca's asset position with regard to FPF-1 may well be correct I suspect.

I will raise this with IC before the next reporting, they are usually quite good at digging into these things.

Doug

<< Previous

Bullboard Posts

Next >>

Defence Therapeutics touts anticancer treatment and immune booster